Organon/Ares Serono Settle Patent Dispute
Dutch company Organon, a subsidiary of Akzo-Nobel, and Swiss group Ares-Serono have settled their patent dispute over the manufacture and use of recombinant fertility hormones (gonadotrophins) after three years' of legal wrangling (Marketletter July 26, 1993), with the two companies agreeing not to dispute each others patents.
The dispute centered on Organon's product Puregon, which allegedly infringed on two Ares-Serono patents. The agreement will allow Organon and its affiliates to have a non-exclusive license for the use of market leader Ares-Serono's recombinant gonadotrophin fertility products. The deal is said to have included an undisclosed payment to the Swiss firm by Organon, which will also pay royalties on worldwide sales to Ares-Serono. Organon is now expected to commence marketing Puregon early next year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze